ADMA BIOLOGICS, INC.
ADMA BIOLOGICS, INC. (ADMA): 88 pipeline candidates · 4 upcoming catalysts · ~33 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
33.4 months
D/E 0.70 · 3% dilution
Lead: Approved
88 candidates
4 upcoming, next in ~1478d
5 buys · 5 sells (180d)
A transparent, data-derived signal for ADMA BIOLOGICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0B
Cash
$138.2M
Quarterly Burn
$22.5M
Runway
33.4 mo
Revenue
$114.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (88 candidates)
| Drug | Phase |
|---|---|
| Adavosertib | Phase 2 |
| Afatinib | Phase 2 |
| Afatinib Dimaleate | Phase 2 |
| Alpelisib | Phase 2 |
| amicidin-β topical solution - | Phase 1 |
| ASCENIV | Approved |
| AZD1775 | Phase 2 |
| BET Bromodomain Inhibitor ZEN-3694 | Phase 1 |
| Binimetinib | Phase 2 |
| BIVIGAM | Approved |
Showing 10 of 88 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
355
Total value held
$1.87B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 36,830,774 | $331.8M |
| vanguard capital management llc | 20,613,742 | $185.7M |
| state street corp | 14,084,205 | $126.9M |
| vanguard portfolio management llc | 8,868,657 | $79.9M |
| citadel advisors llc | 6,247,242 | $56.3M |
| geode capital management, llc | 5,824,116 | $52.5M |
| caligan partners lp | 5,056,511 | $45.6M |
| dimensional fund advisors lp | 5,005,481 | $45.1M |
| american century companies inc | 4,789,011 | $43.1M |
| invesco ltd. | 4,119,577 | $37.1M |
Showing top 10 of 355 institutional holders of ADMA BIOLOGICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ADMA BIOLOGICS, INC.'s pipeline?
ADMA BIOLOGICS, INC. (ADMA) has 88 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ADMA BIOLOGICS, INC.'s lead drug candidate?
ADMA BIOLOGICS, INC.'s most advanced tracked candidate is Adavosertib (Phase 2) for Recurrent Fallopian Tube Carcinoma; Advanced Lymphoma.
What is ADMA BIOLOGICS, INC.'s next catalyst?
ADMA BIOLOGICS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: GILOTRIF" — expected July 5, 2030.
What is ADMA BIOLOGICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ADMA BIOLOGICS, INC. has approximately 33.4 months of cash runway.
What is ADMA BIOLOGICS, INC.'s market capitalization?
ADMA BIOLOGICS, INC.'s market capitalization is approximately $2.0B.
Get the full picture on ADMA BIOLOGICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.